A Phase 1, Open Label, Single Dose, Parallel-group Study to Investigate the Pharmacokinetics of the Fixed Combination of 900 IU r-hFSH and 450 IU r-hLH Given as Pergoveris®, Administered Subcutaneously in Pituitary-suppressed Healthy Premenopausal Female Participants of Japanese or Caucasian Origin
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Ethinylestradiol/desogestrel (Primary) ; Follitropin alfa/lutropin alfa (Primary)
- Indications Female infertility
- Focus Pharmacokinetics
Most Recent Events
- 12 Dec 2025 New trial record